MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    EFFECTS OF DOPAMINERGIC MEDICATION ON REACTIVE AND PROACTIVE INHIBITORY CONTROL

    G. Mirabella, C. Mancini, O. Olivola, A. Rizzardi, V. Di Caprio, E. Ferrari, N. Modugno, A. Pilotto, A. Padovani (Brescia, Italy)

    Objective: In this study, we aim to address the effects of dopaminergic treatment (DT) on the two domains of motor inhibition [1], i.e., reactive (the…
  • 2022 International Congress

    COVID-19 encephalitis with anti-mGluR1 antibody-positive cerebellar ataxia

    F. Cheng, K. Tang, X. Wang (Kingston upon Hull, United Kingdom)

    Objective: To describe a unique case of anti-metabotropic glutamate receptor 1 (mGluR1) antibody (Ab)-mediated cerebellar ataxia post-COVID-19 encephalitis. Background: Cerebellar syndrome is increasingly recognised in…
  • 2022 International Congress

    Japanese cases of Sez6l2 autoimmunity

    M. Abe, H. Yaguchi, A. Kudo, A. Nagai, S. Shirai, I. Iwata, M. Matsushima, A. Kimura, T. Shimohata, I. Yabe (Sapporo-shi, Japan)

    Objective: We aimed to establish a method for measuring anti-Sez6l2 antibody and to clarify how many patients with anti-Sez6l2 antibody-associated cerebellar ataxia (CA) exist in…
  • 2022 International Congress

    Determination of metabotropic glutamate receptor 2/3 distribution with [3H]-LY-341,495 in Parkinson’s disease patients with visual hallucinations

    D. Bedard, E. Kim, I. Frouni, P. Huot (Montreal, Canada)

    Objective: To determine the distribution and levels of metabotropic glutamate 2/3 (mGlu2/3) receptors in brain tissue from patients with Parkinson’s disease (PD) with visual hallucinations (VHs).…
  • 2022 International Congress

    Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study

    R. Costa, J. Ferreira, D. Magalhães, J-F. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: This study aims to evaluate the effects of opicapone (OPC) 50 mg treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’.…
  • 2022 International Congress

    Socio-economic factors influencing Parkinson’s disease self-management

    L. Ambrosio, C. Rodríguez-Blazquez, M. Rodriguez Violante, T. Arakaki, N. Garretto, M. Serrano-Dueñas, I. Ibañez (Southampton, United Kingdom)

    Objective: To identify the socioeconomical factors associated with self-management Parkinson’s disease (PD). Background: Understanding and evaluating how PD patients manage their disease is paramount to…
  • 2022 International Congress

    Challenges and Opportunities People with Parkinson’s Disease Experienced Pre and Post-Covid-19 Vaccination

    L. Currens, S. Carbone, J. Quast, W. Deeb (Worcester, USA)

    Objective: To determine the specific challenges and opportunities people with Parkinson’s disease (PWP) experienced before and after receiving the Covid-19 vaccine. Background: The Covid-19 pandemic…
  • 2022 International Congress

    Aberrant Volume-wise and Voxel-wise Concordance among Dynamic Intrinsic Brain Activity Indices in Parkinson’s Disease

    T. Yuan, L. Kai, S. Wen (Beijing, China)

    Objective: We sought to explore the concordance between the dynamics of different rs-fMRI regional indices in order to better understand  intrinsic brain activity (IBA)  alterations and…
  • 2022 International Congress

    The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson’s Disease

    N. Piniella, N. Burt, S. Yasin, N. Volino, M. Baker, M. Jung, A. Leder, A. Sousa, L. Hoffman (Glen Head, USA)

    Objective: To determine the feasibility and impact of remote cognitive remediation therapy (CRT) on cognitive function and quality of life (QOL) in patients with Parkinson’s…
  • 2022 International Congress

    Feasibility and acceptability of PDConnect: a collaborative approach to physical activity for people with Parkinson’s.

    J. Jones, L. Alexander, L. Hancock, K. Cooper (Aberdeen, United Kingdom)

    Objective: To evaluate the feasibility and acceptability of a novel collaborative telehealth based physical activity intervention for people with Parkinson’s. Background: The benefits of physical…
  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley